ATKR vs CXT

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong Current Ratio and manageable Debt/Equity, the company is unprofitable on a net basis (Profit Margin: -0.53%, ROE: -1.03%) and facing sharp earnings contraction (YoY EPS Growth: -71.6%). Valuation appears stretched relative to peers with a Forward P/E of 12.23 while operating in a declining revenue environment (Revenue Growth YoY: -4.60%), and the lack of a Graham Number or Altman Z-Score limits confidence in intrinsic value and solvency safety. Although the dividend yield is modestly attractive at 1.80% with a sustainable payout ratio, weak earnings momentum, deteriorating profitability, and neutral insider activity suggest substantial downside risks.

CXT presents a dichotomy between strong top-line growth and deteriorating bottom-line performance. While the Piotroski F-Score of 6/9 indicates a stable financial foundation, the stock is trading at a significant premium to its Graham Number ($35.03) and Intrinsic Value ($17.50). Despite consistent earnings beats and robust revenue growth of 19.5%, the YoY earnings decline of 18% and a severe 31.5% price drop over the last six months suggest a loss of market confidence. The outlook remains neutral as the attractive forward P/E (9.52) is offset by bearish insider sentiment and a strong technical downtrend.